MNLO - Menlo Therapeutics Inc. Summary, Stock Quote and News | Benzinga

Market Overview

4.760 -0.26 (-5.18%)

Data as of Sep 22, 2019

Prev. Close 5.02
Price Open 5.01
Volume 147,130
Day's Range 4.6 - 5.4
52 Wk Range 2.69 - 11.95
50 Day Moving Avg. 4.34
PE Ratio 0
Shares Outstanding 23.95M
Market Cap 114.02M

Trade MNLO stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Stocks That Fell Through 52-Week Lows Wednesday Lisa LevinWed, 07 Aug 2019 14:22:31 -0400
The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering Shanthi RexalineTue, 06 Aug 2019 07:22:08 -0400
New 52-Week Lows For Monday Morning Lisa LevinMon, 05 Aug 2019 13:16:16 -0400
Stocks That Set New 52-Week Lows Friday Morning Lisa LevinFri, 02 Aug 2019 10:46:48 -0400
Menlo Therapeutics Q2 EPS $(0.69) Beats $(0.84) Estimate Benzinga NewsdeskThu, 01 Aug 2019 16:44:30 -0400
Menlo Therapeutics Q1 EPS $(0.81) Down From $(0.72) YoY Benzinga NewsdeskThu, 02 May 2019 17:37:18 -0400
Menlo Therapeutics Announces Publication in the Journal of the American Academy of Dermatology of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis Benzinga NewsdeskMon, 25 Mar 2019 08:35:15 -0400
Cantor Fitzgerald Reiterates Overweight, $25 Target On Menlo Therapeutics As Firm Believes 'A greater appreciation for the company's multiple indication approach for serlopitant will increase earnings estimates to levels not yet reflected in consensus' Benzinga_NewsdeskThu, 28 Feb 2019 12:46:18 -0400
Menlo Therapeutics Q4 EPS $(0.76) Beats $(0.81) Estimate Benzinga NewsdeskWed, 27 Feb 2019 17:12:41 -0400
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs Shanthi RexalineFri, 22 Feb 2019 14:55:45 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference Globe NewswireAug 29, 2019
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data Globe NewswireAug 01, 2019
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference Globe NewswireJul 31, 2019
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing PRNewswireJul 15, 2019
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing PRNewswireJul 15, 2019
Life Science Company Live Investor Conference July 11th PRNewswireJul 09, 2019
Life Science Company Live Investor Conference July 11th PRNewswireJul 09, 2019
Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer Globe NewswireJun 18, 2019
Menlo Therapeutics to Present at Upcoming Investor Conferences Globe NewswireMay 29, 2019
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit Globe NewswireMay 13, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

BELLUS Health Seeks $60 Million U.S. IPO Seeking AlphaSep 04, 2019
Menlo Therapeutics to Present at the HC Wainwright —–st Annual Global Investment Conference GuruFocusAug 29, 2019
Plus Therapeutics leads healthcare gainers; TrovaGene leads the losers Seeking AlphaAug 21, 2019
Mangrove Partners Buys SunCoke Energy Inc, Green Plains Inc, NII Holdings Inc, Sells Stemline ... GuruFocusAug 20, 2019
Menlo Therapeutics (MNLO) Investor Presentation - Slideshow Seeking AlphaAug 15, 2019
Menlo Therapeutics Reports Second Quarter —…–9 Financial Results and Provides Program ... GuruFocusAug 01, 2019
Menlo Therapeutics EPS beats by $0.15 Seeking AlphaAug 01, 2019
RegeneRx And RGN-137 In Epidermolysis Bullosa: The Story Seeking AlphaJul 25, 2019
Menlo Therapeutics And Serlopitant In Dermal Pruritus Seeking AlphaJul 22, 2019
Menlo Therapeutics Offers A Low-Cap Biotech Opportunity With High Potential Seeking AlphaMay 29, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2019	EST	Actual	Surprise
EPS:	-0.840	-0.690	0.1500
Rev:		0.00

Q3 2019	EST	Actual	Surprise
EPS:	Expected 2019-11-06
Rev:	Expected 2019-11-06

Fastest Market News Application
You'll Hear It First On Pro

Login Register for Trial

Company Profile

Read More

Visit company website

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo